Abstract:
Background: Prostatic adenocarcinoma is the 2nd most common cancer in males. It is important to differentiate between prostatic adenocarcinoma and its benign mimickers with novel and reliable immunohistochemical markers for early diagnosis of prostatic adenocarcinoma, (6-transmembrane epithelial antigen of prostate (STEAP1), C-myc and basal cell marker P63 can be helpful in distinguishing prostatic adenocarcinoma from benign lesions.
Aim of the study: -To diagnose prostatic adenocarcinoma and differentiate it from its benign mimickers using STEAP1, C-myc and P63 immunoexpression.
-To evaluate the role of STEAP1 overexpression in prostate cancer initiation and progression.
Materials and methods: Retrospective cross-sectional study was conducted on 20 cases of prostatic adenocarcinoma, 8 cases of high grade prostatic intraepithelial neoplasia (HGPIN) and 18 cases of benign prostatic mimickers. All lesions were submitted for STEAP1, C-myc and P63 immunohistochemistry and the results were correlated with clinicopathological and histopathological parameters.
Results: P63, STEAP1 and C-myc showed highly significant difference in expression in prostatic adenocarcinoma in relation to its benign mimickers (p-value